Table 1 Demographic and clinical characteristics of DLBCL patients.
Healthy individuals | DLBCL patient | ||||
|---|---|---|---|---|---|
Prognostic variables | No. | No. | Discovery cohort (n = 10,%) | Internal validation cohort (n = 100, %) | External validation cohort (n = 160, %) |
Gender | |||||
Male | 21 | 165 | 5.00 | 63.00 | 60.63 |
Female | 14 | 105 | 5.00 | 37.00 | 39.38 |
Age (Years) | |||||
<53 | 16 | 119 | 7.00 | 47.00 | 40.63 |
≥53 | 19 | 151 | 3.00 | 53.00 | 59.38 |
Histological Subgroup | |||||
GCB | 132 | 5.00 | 37.00 | 56.25 | |
Non-GCB | 138 | 5.00 | 63.00 | 43.75 | |
Clinical stage | |||||
I | 45 | 3.00 | 15.00 | 16.88 | |
II | 77 | 0.00 | 18.00 | 36.88 | |
III | 77 | 3.00 | 28.00 | 28.75 | |
IV | 71 | 4.00 | 39.00 | 17.50 | |
Final recurrence status | |||||
with | 32 | 1.00 | 13.00 | 11.25 | |
without | 238 | 9.00 | 87.00 | 88.75 | |
B symptoms | |||||
with | 47 | 2.00 | 19.00 | 16.25 | |
without | 223 | 8.00 | 81.00 | 83.75 | |
IPI Scores | |||||
0 | 24 | 1.00 | 21.00 | 1.25 | |
1 | 42 | 4.00 | 24.00 | 8.75 | |
2 | 82 | 3.00 | 14.00 | 40.63 | |
3 | 73 | 2.00 | 27.00 | 27.50 | |
4 | 49 | 0.00 | 14.00 | 21.88 | |
